On-target restoration of a split T cell-engaging antibody for precision immunotherapy

[1]  A. Nenes.  RESPONSES , 2020, Jerusalem's Survival, Sennacherib's Departure, and the Kushite Role in 701 BCE.

[2]  Janice M Reichert,et al.  Antibodies to watch in 2019 , 2018, mAbs.

[3]  James J. Collins,et al.  Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses , 2018, Cell.

[4]  R. Brentjens,et al.  Development of CAR T cells designed to improve antitumor efficacy and safety. , 2017, Pharmacology & therapeutics.

[5]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[6]  B. Oliva,et al.  Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains , 2016, Scientific Reports.

[7]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[8]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[9]  G. Weiner.  Building better monoclonal antibody-based therapeutics , 2015, Nature Reviews Cancer.

[10]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[11]  Loren Gragert,et al.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. , 2014, The New England journal of medicine.

[12]  R. Morgan.  Risky business: target choice in adoptive cell therapy. , 2013, Blood.

[13]  L. Domingues,et al.  The novel Fh8 and H fusion partners for soluble protein expression in Escherichia coli: a comparison with the traditional gene fusion technology , 2013, Applied Microbiology and Biotechnology.

[14]  Raphael Sandaltzopoulos,et al.  Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo , 2013, Cancer Immunology Research.

[15]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[16]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[17]  R. Kontermann.  Dual targeting strategies with bispecific antibodies , 2012, mAbs.

[18]  M. Zöller.  CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? , 2011, Nature Reviews Cancer.

[19]  G. Mann,et al.  An extended antibody microarray for surface profiling metastatic melanoma. , 2010, Journal of immunological methods.

[20]  Thomas Singer,et al.  The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.

[21]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[22]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[23]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[24]  J. Pagel,et al.  A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. , 2006, Cancer research.

[25]  R. Christopherson,et al.  Multiplex detection of surface molecules on colorectal cancers , 2006, Proteomics.

[26]  R. Kimmig,et al.  MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. , 2006, Molecular immunology.

[27]  D. Röthlisberger,et al.  Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. , 2005, Journal of molecular biology.

[28]  T. Beddoe,et al.  Crystal structure of the human T cell receptor CD3εγ heterodimer complexed to the therapeutic mAb OKT3 , 2004 .

[29]  Andreas Plückthun,et al.  Biophysical properties of human antibody variable domains. , 2003, Journal of molecular biology.

[30]  Watt W Webb,et al.  Biological and chemical applications of fluorescence correlation spectroscopy: a review. , 2002, Biochemistry.

[31]  W. Ouwehand,et al.  The isolation and characterisation of human monoclonal HLA-A2 antibodies from an immune V gene phage display library. , 2000, Tissue antigens.

[32]  B. Sandmaier,et al.  Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. , 1998, Biophysical journal.

[33]  Kouhei Tsumoto,et al.  Open sandwich ELISA: A novel immunoassay based on the interchain interaction of antibody variable region , 1996, Nature Biotechnology.

[34]  E. Voss,et al.  Comparative Properties of the Single Chain Antibody and Fv Derivatives of mAb 4-4-20 , 1996, The Journal of Biological Chemistry.

[35]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Poljak,et al.  Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution , 1986, Science.

[37]  David Brink,et al.  : A Review of the , 2018 .

[38]  A. Younes,et al.  Novel immunotherapies in lymphoid malignancies , 2016, Nature Reviews Clinical Oncology.

[39]  G. Winter,et al.  Making antibodies by phage display technology. , 1994, Annual review of immunology.